



C E P I



Vaccinopolis
University of Antwerp

Enabling the Evaluation of COVID-19 Vaccines with Correlates of Protection Vaccinopolis University of Antwerp, Belgium February 16 - 17, 2023



Jerry P Weir, PhD

Director, Division of Viral Products
20993 Silver Spring, MD USA
Food & Drug Administration
10903 New Hampshire Ave

Tel: +1 240-402-7473

E-mail: jerry.weir@fda.hhs.gov

Dr. Jerry P. Weir is the Director of the Division of Viral Products (DVP), Office of Vaccines Research and Review with the U.S. Food and Drug Administration's Center for Biologics Evaluation and Research (CBER). He received his PhD in Biochemistry from Vanderbilt University and did postdoctoral research in virology at the National Institutes of Health. He joined the Food and Drug Administration in 1994. In his position as Director of DVP, Dr. Weir manages the regulatory activities and research programs of the Division. As a Senior Investigator at CBER, he directs a research program pertaining to diverse viruses, including SARS-CoV-2, influenza, herpesviruses, and poxviruses. Dr. Weir frequently serves as an advisor to the World Health Organization on issues relating to influenza virus vaccines activities and vaccine standards.

